Pancreatic Cancer Therapy Shows Quality of Life and Pain Benefits in Phase 3 Trial

Novocure announced that JAMA Network Open published secondary analysis data from its Phase 3 PANOVA-3 trial for unresectable, locally advanced pancreatic adenocarcinoma. The findings indicate that Tumor Treating Fields (TTFields) therapy, combined with chemotherapy, improved overall survival and provided significant benefits in pain management and patient quality of life. This peer-reviewed publication offers important evidence for the oncology community.